Posts Tagged ‘Immunosupression

Immediate adverse events attributed to infliximab infusion by the treating gastroenterologist were infrequent (7%), and generally minor and self-limited; only one patient required discontinuation of therapy due to an anaphylactic-type infusion reaction. Similar infusion-related adverse events were seen in the data available from the retrospective clinical practice reviews from Rochester Minnesota (19%), Chicago, Illinois (6%), […]

When the results of the retrospective Edmonton clinical practice review were compared with those reported in the randomized, placebo controlled, clinical trial with infliximab, the response rates were found to be similar (73% and 81%, respectively). Nevertheless, the complete response rate was lower in the present study than in the earlier studies (17% and 48%, […]

One hundred three of 109 patients with Crohn’s disease in our study had failed to achieve remission with corticosteroids. Initiating infliximab treatment in this corticosteroid-refractory group of patients achieved an overall clinical response rate in all disease groups of 73% (17% complete response and 55% partial response). The results of our Edmonton retrospective clinical practice […]

Our initial clinical experience with infliximab for the treatment of Crohn’s disease correlates well with the initial placebo controlled studies, as well as with three retrospective studies from the United States describing response and adverse events in clinical practice settings. Very cheap drugs at your disposal – buy mircette to get best deals at best […]

Maintenance treatment with infliximab Of the initial 80 patients who demonstrated a response to infliximab, 43 received one to eight additional infusions of infliximab to maintain response, with a median interval of eight weeks (range four to 56 weeks). Forty of the 43 patients continued to respond clinically to a second infusion of infliximab. Of […]

The patient demographics and characteristics did not differ significantly between responders and nonresponders (Table 3). Furthermore, response rates did not differ between those with and those without concomitant immune modifiers (75% and 71%, respectively; P=0.568), or with the number of infliximab infusions used for induction (one-, two- or three-dose infliximab: 73%, 100% and 73%, respectively; […]

Infliximab-induced clinical response The clinical outcomes of the 109 patients are shown in Table 2. The median time to response was two weeks (range one to six weeks), and the median duration of response was 12 weeks (range six to 88 weeks). Overall, a clinical response (complete or partial as defined above in the ‘Methods’) […]

top